A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06238479

Public ClinicalTrials.gov record NCT06238479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase 1a (dose-escalation, dose-optimization) and phase 1b (dose-expansion). The study will last up to approximately 4 years. Eligible patients will have the option to continue taking study drug after the study is complete.

Study identification

NCT ID: NCT06238479
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 490 participants

Conditions and interventions

Conditions

Interventions

LY4101174 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 5, 2024 (Actual)
Primary completion: Mar 2027 (Estimated)
Completion: Apr 2027 (Estimated)
Last update posted: May 22, 2026

2024 – 2027

United States locations

U.S. sites: 9
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
AdventHealth Orlando	Orlando	Florida	32804	—
Emory University	Atlanta	Georgia	30322	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola	New York	11501	—
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
UT Southwestern Medical Center	Dallas	Texas	75390-8884	—
South Texas Accelerated Research Therapeutics (START)	San Antonio	Texas	78229-3307	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06238479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 22, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06238479 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →